Dr. Reddy's Can't Kill Arthritis Drug Patent Suit Yet

Law360 (November 8, 2019, 7:08 PM EST) -- A New Jersey federal judge refused Dr. Reddy’s Laboratories Inc.’s bid to invalidate two of Horizon Pharma Inc.’s patents for arthritis drug Vimovo, ruling Thursday that the generic-drug maker hasn’t shown the patents lack an adequate written description.

Ruling on a summary judgment motion in the patent suit brought by Horizon, U.S. District Judge Stanley Chesler rejected Dr. Reddy’s reliance on the Federal Circuit’s ruling earlier this year in another patent case the pharmaceutical company had faced. The instant case targets Dr. Reddy’s and Mylan Pharmaceuticals Inc. over their plans to manufacture and market generic versions of Vimovo.

Dr. Reddy’s argued...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS